Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 29, 2019
Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients
Vasiliki Nikolaou, D Voudouri, G Tsironis, et al.
British Journal of Cancer
|
November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
N G Gavalas, M Tsiatas, O Tsitsilonis, et al.
Cancer
|
May 15, 1996
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival
A Bamias, M E Hill, D Cunningham, et al.
Gynecologic Oncology
|
April 17, 2007
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance
A Bamias, M L Tsiatas, E Kafantari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2007
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
P A Kosmidis, H P Kalofonos, C Christodoulou, et al.
ESMO Open
|
July 8, 2026
A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)
S J Shin, J L Lee, T Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
R Elaidi, A Harbaoui, B Beuselinck, et al.
British Journal of Cancer
|
June 29, 2013
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
A Bamias, K Tzannis, B Beuselinck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group
M A Dimopoulos, C Bakoyannis, V Georgoulias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)
K Fujiwara, B J Monk, C Lhommé, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 29, 2019
Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients
Vasiliki Nikolaou, D Voudouri, G Tsironis, et al.
British Journal of Cancer
|
November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
N G Gavalas, M Tsiatas, O Tsitsilonis, et al.
Cancer
|
May 15, 1996
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival
A Bamias, M E Hill, D Cunningham, et al.
Gynecologic Oncology
|
April 17, 2007
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance
A Bamias, M L Tsiatas, E Kafantari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2007
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
P A Kosmidis, H P Kalofonos, C Christodoulou, et al.
ESMO Open
|
July 8, 2026
A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)
S J Shin, J L Lee, T Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
R Elaidi, A Harbaoui, B Beuselinck, et al.
British Journal of Cancer
|
June 29, 2013
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
A Bamias, K Tzannis, B Beuselinck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group
M A Dimopoulos, C Bakoyannis, V Georgoulias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)
K Fujiwara, B J Monk, C Lhommé, et al.
Page
of 9